tradingkey.logo
搜尋

Ginkgo Bioworks Holdings Inc

DNA
添加自選
10.400USD
+0.110+1.07%
收盤 07/02, 13:00美東報價延遲15分鐘
641.27M總市值
虧損本益比TTM

Ginkgo Bioworks Holdings Inc

10.400
+0.110+1.07%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.07%

5天

+1.46%

1月

+14.92%

6月

+19.54%

今年開始到現在

+25.15%

1年

-18.24%

關鍵數據
10.310今開
11.090最高
865.45K成交量
虧損本益比TTM
--本益比動
--股利TTM
1.40%換手率
10.280昨收
10.150最低
4.79M成交額
虧損本益比靜
1.45市淨率
0.00%股息率 TTM
-26.26%ROA
17.58052週最高
0.97量比
-547.03M淨利潤
61.66M總股本
-5.3493每股盈餘TTM
1.80Beta
-56.03%ROE
5.37052週最低
9.14%振幅
84.09%毛利率
641.27M總市值
2.59回報/風險
5.25%風險率

TradingKey Ginkgo Bioworks Holdings Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Ginkgo Bioworks Holdings Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名183/387位。機構持股佔比非常高,近一月多位分析師給出公司評級為賣出。最高目標價為10.00。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Ginkgo Bioworks Holdings Inc評分

相關信息

行業排名
183 / 387
全市場排名
337 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Ginkgo Bioworks Holdings Inc亮點

亮點風險
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
估值合理
公司最新PE估值-1.94,處於3年歷史合理位
機構減倉
最新機構持股33.44M股,環比減少12.65%
安德烈亞斯·霍爾沃森持倉
明星投資者安德烈亞斯·霍爾沃森持倉,最新持倉2.52M股

分析師目標

基於 3 分析師
賣出
評級
10.000
目標均價
-2.72%
漲幅空間

Ginkgo Bioworks Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Ginkgo Bioworks Holdings Inc簡介

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代碼DNA
公司Ginkgo Bioworks Holdings Inc
CEOKelly (Jason)
網址https://investors.ginkgobioworks.com/

常見問題

Ginkgo Bioworks Holdings Inc(DNA)的當前股價是多少?

Ginkgo Bioworks Holdings Inc(DNA)的當前股價是 10.40。

Ginkgo Bioworks Holdings Inc 的股票代碼是什麼?

Ginkgo Bioworks Holdings Inc的股票代碼是DNA。

Ginkgo Bioworks Holdings Inc股票的52週最高點是多少?

Ginkgo Bioworks Holdings Inc股票的52週最高點是17.58。

Ginkgo Bioworks Holdings Inc股票的52週最低點是多少?

Ginkgo Bioworks Holdings Inc股票的52週最低點是5.37。

Ginkgo Bioworks Holdings Inc的市值是多少?

Ginkgo Bioworks Holdings Inc的市值是605.36M。

現在Ginkgo Bioworks Holdings Inc(DNA)的股票是買入、持有還是賣出?

根據分析師評級,Ginkgo Bioworks Holdings Inc(DNA)的總體評級為賣出,目標價格為10.00。

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是多少

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是-5.64。